Guru Sonpavde

Summary

Affiliation: US Oncology
Country: USA

Publications

  1. ncbi Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials
    Thomas E Hutson
    Genitourinary Oncology Program, Texas Oncology, PA, Baylor Sammons Cancer Center, Dallas, TX 75246, USA
    Clin Genitourin Cancer 5:S31-9. 2006
  2. doi Satraplatin for the therapy of castration-resistant prostate cancer
    Guru Sonpavde
    Texas Oncology, Baylor College of Medicine, Webster, TX 77598, USA
    Future Oncol 5:931-40. 2009
  3. pmc Novel agents for advanced bladder cancer
    Guru Sonpavde
    Genitourinary Oncology Program, Texas Oncology, Veterans Affairs Medical Center, Baylor College of Medicine, 501 Medical Center Blvd, Webster, TX 77598, USA
    Ther Adv Med Oncol 1:37-50. 2009
  4. doi Objective measures of physical functional capacity warrant exploration to complement or replace the subjective physician estimated performance status
    Guru Sonpavde
    Texas Oncology, Section of Medical Oncology, Michael E DeBakey Veterans Affairs Medical Center, USA
    Am J Clin Oncol 35:163-6. 2012
  5. doi Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy
    Guru Sonpavde
    U S Oncology Research, Inc, Texas Oncology and Baylor College of Medicine, Webster, TX 77598, USA
    Urol Oncol 30:607-13. 2012
  6. doi Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer
    Guru Sonpavde
    US Oncology Research, Inc, The Woodlands, TX 77380, USA
    Urol Oncol 29:682-9. 2011
  7. doi Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer
    G Sonpavde
    Texas Oncology and US Oncology Research, Houston, TX, USA
    Ann Oncol 23:1803-8. 2012
  8. doi The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature
    Guru Sonpavde
    Texas Oncology, Houston, TX, USA
    Eur Urol 61:639-47. 2012
  9. doi Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community
    Guru Sonpavde
    Texas Oncology, Houston, TX, USA
    Clin Genitourin Cancer 10:1-5. 2012
  10. ncbi Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer
    Guru Sonpavde
    Genitourinary Oncology Program, U S Oncology Research, Houston, Texas, USA
    Cancer 110:2628-39. 2007

Collaborators

Detail Information

Publications87

  1. ncbi Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials
    Thomas E Hutson
    Genitourinary Oncology Program, Texas Oncology, PA, Baylor Sammons Cancer Center, Dallas, TX 75246, USA
    Clin Genitourin Cancer 5:S31-9. 2006
    ..Combinations of these agents are being evaluated. Clinical trials designed to further assess these and other agents need to be vigorously supported...
  2. doi Satraplatin for the therapy of castration-resistant prostate cancer
    Guru Sonpavde
    Texas Oncology, Baylor College of Medicine, Webster, TX 77598, USA
    Future Oncol 5:931-40. 2009
    ..Further development is ongoing with the evaluation of combination regimens containing satraplatin in other solid tumors. In addition, efforts are ongoing to select patients who are more likely to benefit from satraplatin...
  3. pmc Novel agents for advanced bladder cancer
    Guru Sonpavde
    Genitourinary Oncology Program, Texas Oncology, Veterans Affairs Medical Center, Baylor College of Medicine, 501 Medical Center Blvd, Webster, TX 77598, USA
    Ther Adv Med Oncol 1:37-50. 2009
    ..Recent and ongoing trials of novel chemotherapeutic and biologic agents are reviewed...
  4. doi Objective measures of physical functional capacity warrant exploration to complement or replace the subjective physician estimated performance status
    Guru Sonpavde
    Texas Oncology, Section of Medical Oncology, Michael E DeBakey Veterans Affairs Medical Center, USA
    Am J Clin Oncol 35:163-6. 2012
    ..We explore and discuss attractive candidates for objective measures of physical functioning...
  5. doi Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy
    Guru Sonpavde
    U S Oncology Research, Inc, Texas Oncology and Baylor College of Medicine, Webster, TX 77598, USA
    Urol Oncol 30:607-13. 2012
    ..We evaluated the association of changes in ALP within 90 days with OS in men with CRPC and bone metastases treated with docetaxel or mitoxantrone in the TAX327 trial...
  6. doi Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer
    Guru Sonpavde
    US Oncology Research, Inc, The Woodlands, TX 77380, USA
    Urol Oncol 29:682-9. 2011
    ..A phase II trial evaluated azacitidine for men with castration-resistant prostate cancer (CRPC) progressing on combined androgen blockade (CAB)...
  7. doi Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer
    G Sonpavde
    Texas Oncology and US Oncology Research, Houston, TX, USA
    Ann Oncol 23:1803-8. 2012
    ..A randomized, double-blind, placebo-controlled phase II trial compared DP combined with either AT-101 (A) or placebo in chemonaive mCRPC...
  8. doi The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature
    Guru Sonpavde
    Texas Oncology, Houston, TX, USA
    Eur Urol 61:639-47. 2012
    ....
  9. doi Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community
    Guru Sonpavde
    Texas Oncology, Houston, TX, USA
    Clin Genitourin Cancer 10:1-5. 2012
    ..The frequency of cisplatin-based chemotherapy administration in patients with advanced UC in community-based cancer centers is unknown...
  10. ncbi Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer
    Guru Sonpavde
    Genitourinary Oncology Program, U S Oncology Research, Houston, Texas, USA
    Cancer 110:2628-39. 2007
    ..Recent and ongoing studies of neoadjuvant therapy followed by prostatectomy were reviewed...
  11. doi Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy
    Guru Sonpavde
    Texas Oncology and Baylor Sammons Cancer Center, Dallas, TX, USA
    Clin Genitourin Cancer 6:134-7. 2008
    ..Sunitinib 50 mg daily was administered orally on days 1-28 of each 6-week cycle. Patients were treated to a maximum of 8 cycles or until clinically progressive disease or intolerable toxicity...
  12. ncbi Novel agents for muscle-invasive and advanced urothelial cancer
    Guru Sonpavde
    US Oncology Research, Baylor College of Medicine, Houston, TX 77598, USA
    BJU Int 101:937-43. 2008
    ..Recent and ongoing trials of novel chemotherapeutic and biologic agents are reviewed...
  13. ncbi Vaccine therapy for prostate cancer
    Guru Sonpavde
    U S Oncology Research and the Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Houston, TX 77598, USA
    Urol Oncol 25:451-9. 2007
    ..Efforts to optimize vaccine approaches and select ideal patient populations need to continue because there is no evidence supporting a single superior approach...
  14. ncbi Current optimal chemotherapy for advanced urothelial cancer
    Guru Sonpavde
    US Oncology Research and Texas Oncology PA, 501 Medical Center Blvd, Webster, TX 77598, USA
    Expert Rev Anticancer Ther 8:51-61. 2008
    ..The profusion of novel biologic agents offers the promise of improved outcomes. A multidisciplinary approach is necessary to make therapeutic advances...
  15. doi Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma
    Guru Sonpavde
    Genitourinary Oncology Program, Texas Oncology, PA, US Oncology Research, 501 Medical Center Blvd, Webster, TX 77598, USA
    Expert Opin Investig Drugs 17:253-61. 2008
    ..Pazopanib (GW-786034) is a second-generation multitargeted tyrosine kinase inhibitor against VEGFR-1, 2 and 3, platelet-derived growth factor receptor (PDGFR)-alpha, PDGFR-beta and c-kit...
  16. ncbi Neoadjuvant chemotherapy for bladder cancer
    Guru Sonpavde
    Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Webster 77598, USA
    Oncology (Williston Park) 21:1673-81; discussion 1686-8, 1691, 1694. 2007
    ..Patients who are either unfit for or refuse radical cystectomy may benefit from neoadjuvant chemotherapy with or without radiation to enable bladder preservation...
  17. doi Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy
    Guru Sonpavde
    US Oncology Research, Inc, 501 Medical Center Blvd, Webster, TX 77598, USA
    Clin Genitourin Cancer 5:457-9. 2007
    ..Correlative studies will be performed to detect the biologic activity of azacitidine (increased fetal hemoglobin, plasma DNA methylation) and examine any association with anti-tumor clinical activity...
  18. doi Treatment of metastatic urothelial cancer: opportunities for drug discovery and development
    Guru Sonpavde
    US Oncology Research, Texas Oncology, PA, USA
    BJU Int 102:1354-60. 2008
    ..Recent and ongoing trials of novel chemotherapeutic and biological agents are reviewed...
  19. doi Patient selection for phase II trials
    Guru Sonpavde
    Texas Oncology, P A, Dallas, Texas, USA
    Am J Clin Oncol 32:216-9. 2009
    ..Such trials may be superior guides to select regimens for further development than trials that are single-center based with favorable populations...
  20. doi Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy
    G Sonpavde
    US Oncology Research, Inc, Houston, TX, USA
    Ann Oncol 21:319-24. 2010
    ..This phase II trial evaluated sunitinib malate in patients with progressing metastatic CRPC following prior docetaxel...
  21. doi Neoadjuvant therapy preceding prostatectomy for prostate cancer: rationale and current trials
    Guru Sonpavde
    Texas Oncology, Baylor College of Medicine, TX, USA
    Expert Rev Anticancer Ther 10:439-50. 2010
    ..This promising modality may aid the rapid development of novel therapeutic agents. A multidisciplinary approach involving oncologists, urologists and pathologists is critical to the success of this model...
  22. doi Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium
    Guru Sonpavde
    Texas Oncology, Baylor College of Medicine, Houston, TX 77598, USA
    Lancet Oncol 11:861-70. 2010
    ..A multidisciplinary approach is necessary to make therapeutic advances. This review discusses current second-line therapy and emerging drugs for advanced transitional-cell carcinoma...
  23. doi Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy
    Guru Sonpavde
    Michael E DeBakey Veterans Affairs Medical Center, Houston, TX, USA
    BJU Int 108:687-92. 2011
    ..To stratify risk of pathological (p) T2N0 urothelial carcinoma of the bladder after radical cystectomy (RC) based on pathological factors to facilitate the development of adjuvant therapy trials for high-risk patients...
  24. doi Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?
    Guru Sonpavde
    Texas Oncology and Veterans Affairs Medical Center, Baylor College of Medicine, 501 Medical Center Blvd, Webster, TX 77598, USA
    Eur Urol 61:307-16. 2012
    ..The expanding armamentarium of agents for the therapy of advanced clear cell renal cell carcinoma (RCC) warrants further investigation of optimal patient selection...
  25. ncbi Perioperative chemotherapy for bladder cancer
    Guru Sonpavde
    Texas Oncology, P A and The Baylor College of Medicine, Houston, TX, USA
    Crit Rev Oncol Hematol 57:133-44. 2006
    ..In patients who are either unfit for or refuse radical cystectomy, neoadjuvant chemotherapy with or without radiation can render bladder preservation possible in patients who attain pathologic major response...
  26. ncbi Hormone refractory prostate cancer: Management and advances
    Guru Sonpavde
    US Oncology Research Network Houston, TX, USA
    Cancer Treat Rev 32:90-100. 2006
    ....
  27. ncbi New approaches in hormone refractory prostate cancer
    Guru Sonpavde
    U S Oncology Research Network, Houston, TX, USA
    Am J Clin Oncol 29:196-201. 2006
    ....
  28. ncbi Management of recurrent testicular germ cell tumors
    Guru Sonpavde
    US Oncology Research, Houston, Texas, USA
    Oncologist 12:51-61. 2007
    ..Salvage surgical resection has an important role in selected patients. Cisplatin-refractory patients have a poor prognosis with current therapy, and novel chemotherapeutic and biologic agents need to be discovered for such patients...
  29. ncbi Bladder cancer update. Current evaluation methods and standard of care
    Guru Sonpavde
    Texas Oncology, PA, Deke Slayton Cancer Center, Webster 77598, USA
    Postgrad Med 119:30-7. 2006
    ..He focuses in particular on management of transitional cell carcinoma, which is responsible for about 95% of cases...
  30. ncbi Systemic chemotherapy for urothelial cancer
    Guru Sonpavde
    Texas Oncology, PA, Webster, TX 77598, USA
    Clin Genitourin Cancer 5:34-42. 2006
    ..With the unraveling of bladder cancer biology and the discovery of novel agents targeting several carcinogenic pathways, the future of therapy for transitional cell carcinoma appears promising...
  31. doi Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer
    Matthew D Galsky
    US Oncology Research, McKesson Specialty Health, The Woodlands, TX, USA
    Clin Genitourin Cancer 11:175-81. 2013
    ..We investigated the efficacy and safety of gemcitabine, cisplatin, and sunitinib (GCS) in mUC and MIBC in parallel phase II trials...
  32. doi Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer
    Guru Sonpavde
    Michael E DeBakey Veterans Affairs Medical Center, Houston, Texas, USA
    J Urol 185:456-61. 2011
    ..We identified an association between disease-free survival at 2 to 3 years and 5-year overall survival...
  33. doi Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling
    Jonathan M Levitt
    Scott Department of Urology, Baylor College of Medicine, Houston, Texas, USA
    Mol Cancer Ther 9:1128-35. 2010
    ..Further clinical development might be warranted in selected human subjects...
  34. doi Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer
    Mark T Fleming
    US Oncology Research, McKesson Specialty Health, The Woodlands, TX, USA
    Clin Genitourin Cancer 10:6-14. 2012
    ..The efficacy of combining cetuximab with mitoxantrone (M) plus prednisone (MP) was evaluated in progressive metastatic castrate-resistant prostate cancer (CRPC) after receiving docetaxel...
  35. ncbi Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma
    Guru Sonpavde
    U S Oncology Research, Webster, Texas, USA
    Urology 69:1221-6. 2007
    ..To evaluate estrogen receptors as a therapeutic target for human bladder cancer...
  36. pmc Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy
    Guru Sonpavde
    Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Houston, Texas, USA
    Cancer 115:4104-9. 2009
    ....
  37. doi Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy
    Guru Sonpavde
    Michael E DeBakey Veterans Affairs Medical Center, Dallas, Texas, USA
    J Urol 185:1216-21. 2011
    ....
  38. pmc The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy
    Guru Sonpavde
    Texas Oncology and Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Houston, Texas, USA
    Cancer 117:3963-71. 2011
    ..In men with metastatic castration-resistant prostate cancer (CRPC), the association of measurable tumor responses with overall survival (OS) is unknown. The authors retrospectively evaluated the TAX327 phase 3 trial to study this relation...
  39. doi Neoadjuvant chemotherapy for invasive bladder cancer
    Guru Sonpavde
    Michael E DeBakey Veterans Affairs Medical Center, Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Houston, TX 77030, USA
    Curr Urol Rep 13:136-46. 2012
    ..Given that bladder cancer is characterized by initial localized presentation in the vast majority of cases, the paradigm of neoadjuvant therapy may expedite the development of novel systemic agents...
  40. ncbi Neoadjuvant chemotherapy preceding cystectomy for bladder cancer
    Guru Sonpavde
    Texas Oncology, P A and US Oncology Research, 501 Medical Center Blvd, Webster, TX 77598, USA
    Expert Opin Pharmacother 9:1885-93. 2008
    ..Occult micrometastasis at the time of radical cystectomy leads predominantly to distant failures in patients with locally advanced, muscle-invasive transitional cell carcinoma of the bladder...
  41. doi Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model
    Guru Sonpavde
    Texas Oncology, P A and U S Oncology Research, Houston, TX 77030, USA
    Urol Oncol 27:391-9. 2009
    ..Angiogenesis and VEGF expression correlate with poor outcomes in human urothelial carcinoma. We designed a preclinical study to examine the efficacy of sunitinib alone and in combination with cisplatin against human urothelial carcinoma...
  42. doi Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine
    Weiguo Jian
    Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA
    Mol Cancer Ther 8:1772-8. 2009
    ..IHC showed reduced Ki-67 and CD31 and increased cleaved caspase-3 with combination therapy compared with controls. Enzastaurin showed preclinical antitumor activity against human TCC and enhanced the activity of gemcitabine...
  43. doi Pazopanib for the treatment of renal cell carcinoma and other malignancies
    Guru Sonpavde
    Texas Oncology, USA
    Drugs Today (Barc) 45:651-61. 2009
    ..Ongoing trials are further evaluating pazopanib in a variety of other malignancies...
  44. doi Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials
    Guru Sonpavde
    Department of Medicine, Section of Medical Oncology, University of Alabama at Birmingham UAB, AL, USA
    Crit Rev Oncol Hematol 87:80-9. 2013
    ..85 (95% CI: 0.58-1.25, p=0.41), respectively. No difference in risk was found based on tumor type, age and trial design. The majority of trials exhibited high quality per Jadad scoring and no heterogeneity or publication bias was found...
  45. doi A conventional preclinical schedule of cisplatin is more effective than a metronomic frequent bolus schedule for urothelial carcinoma
    Jonathan M Levitt
    Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA
    Urol Oncol 31:234-40. 2013
    ..We hypothesized that the anti-angiogenic and anti-cell-migratory activity of lower concentrations of cisplatin may confer similar anti-tumor activity and demonstrate less nephrotoxicity than conventional cytotoxic concentrations...
  46. doi The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients
    Guru Sonpavde
    Texas Oncology, Houston, TX, USA
    Curr Oncol Rep 14:295-306. 2012
    ..Appropriate patient selection for VEGF inhibitors and prevention as well as prompt intervention to manage thrombosis and bleeding are necessary to forestall serious morbidities and mortality...
  47. ncbi Frequency of cisplatin administration in patients presenting with advanced urothelial carcinoma in the community
    Guru Sonpavde
    US Oncology Research, LLC, McKesson Specialty Health, The Woodlands, TX, and Deke Slayton Cancer Center, Webster, TX Texas Cancer Registry, Austin, TX US Oncology Research, LLC, The Woodlands, TX US Oncology Research, LLC, Sugarland, TX Baylor Sammons Cancer Center, Dallas, TX Texas Oncology, Austin, TX US Oncology Research, LLC, McKesson Specialty Health, The Woodlands, TX, and Baylor Sammons Cancer Center Texas Oncology PA, Dallas, TX US Oncology Research, LLC, McKesson Specialty Health, The Woodlands, TX, and Comprehensive Cancer Centers of Nevada, Las Vegas, NV
    J Clin Oncol 30:285. 2012
    ..A study was conducted to identify chemotherapy regimens administered by medical oncologists in community-based cancer centers...
  48. ncbi Cytoreductive nephrectomy in the United States: Patterns of care and patient characteristics
    Che Kai Tsao
    Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY Texas Oncology, Houston, TX, and Department of Medicine, Section of Medical Oncology, Michael E DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, Houston, TX
    J Clin Oncol 30:366. 2012
    ..However, first-line systemic therapy for mRCC changed in 2005 with FDA approval of VEGFR tyrosine kinase inhibitor (TKIs). We evaluated the patterns of use of CyNx in the pre- and post-TKI era and characteristics of pts undergoing CyNx...
  49. doi Hypomethylating agents for urologic cancers
    Ajjai S Alva
    Baylor College of Medicine and Michael E DeBakey VA Medical Center, Houston, TX 77030, USA
    Future Oncol 7:447-63. 2011
    ....
  50. doi Contemporary management of metastatic castration-resistant prostate cancer
    Guru Sonpavde
    Texas Oncology, Veterans Affairs Medical Center, Baylor College of Medicine, Houston, Texas, USA
    Curr Opin Urol 21:241-7. 2011
    ..This review will describe the contemporary management of castration-resistant prostate cancer in the context of multiple recent advances...
  51. pmc GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy
    Guru Sonpavde
    Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 17:7174-82. 2011
    ....
  52. ncbi Axitinib for renal cell carcinoma
    Guru Sonpavde
    Genitourinary Oncology Program, Texas Oncology PA, Houston, TX 77598, USA
    Expert Opin Investig Drugs 17:741-8. 2008
    ..Bevacizumab plus IFN may also be added to the therapeutic armamentarium. Axitinib (AG-013736) is an oral and selective tyrosine kinase inhibitor...
  53. ncbi Efficacy of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) exposed to prior ketoconazole (KC)
    Gregory Russell Pond
    McMaster University, Hamilton, ON, Canada Duke Cancer Institute, Durham, NC Ascenta Therapeutics, Malvern, PA US Oncology Research, LLC, McKesson Specialty Health, The Woodlands, TX, and Tisch Cancer Institute, Mount Sinai Medical Center, New York, NY US Oncology Research, LLC, McKesson Specialty Health, The Woodlands, TX, and Deke Slayton Cancer Center, Webster, TX
    J Clin Oncol 30:204. 2012
    ....
  54. doi Immunotherapy for castration-resistant prostate cancer
    Guru Sonpavde
    Department of Medicine, Section of Medical Oncology, University of Alabama at Birmingham UAB Comprehensive Cancer Center, Birmingham, AL 35294, USA
    Urol Clin North Am 39:465-81. 2012
    ..The development of predictive markers for immune response that translate into improved long-term outcomes is important. This article reviews the emerging data and the unique strengths and weaknesses of these approaches...
  55. doi Neoadjuvant systemic therapy for urological malignancies
    Guru Sonpavde
    Texas Oncology, Michael E DeBakey Veterans Affairs Medical Center, Department ofMedicine, Section of Medical Oncology, Baylor College of Medicine, Houston, TX, USA
    BJU Int 106:6-22. 2010
    ..Therefore, the paradigm of neoadjuvant therapy preceding surgery may expedite the development of novel systemic agents and improve outcomes...
  56. doi The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature
    Guru Sonpavde
    Veterans Affairs Medical Centre and the Baylor College of Medicine, Houston, TX, USA
    Eur Urol 60:270-8. 2011
    ..The development of agents targeting androgen signalling holds promise for men with castration-resistant prostate cancer (CRPC)...
  57. doi Clinical and pharmacokinetic evaluation of satraplatin
    Gury Doshi
    Texas Oncology, 925 Gessner, Ste 550, Houston, TX 77024, USA
    Expert Opin Drug Metab Toxicol 8:103-11. 2012
    ..Satraplatin is an investigational third-generation orally available lipophilic platinum, which has demonstrated safety and antitumor activity in multiple settings...
  58. doi Recent advances in immunotherapy for the treatment of prostate cancer
    Guru Sonpavde
    Texas Oncology, Houston, Texas, USA
    Expert Opin Biol Ther 11:997-1009. 2011
    ..Prostate cancer vaccines attempt to induce cancer-specific systemic immune responses and represent a new class of targeted therapies, many of which are non-toxic. Several vaccine technologies are in development...
  59. doi The role of docetaxel based therapy for prostate cancer in the era of targeted medicine
    Guru Sonpavde
    Texas Oncology, Veterans Affairs Medical Center and the Baylor College of Medicine, Houston, Texas, USA
    Int J Urol 17:228-40. 2010
    ..The increased understanding of the mechanisms of progressive castration-resistant prostate cancer is being translated into an increasing pipeline of novel therapies...
  60. ncbi Pazopanib: a novel multitargeted tyrosine kinase inhibitor
    Guru Sonpavde
    Texas Oncology, P A, Baylor Sammons Cancer Center, Dallas, TX 75246, USA
    Curr Oncol Rep 9:115-9. 2007
    ..Phase I clinical trials have revealed manageable toxicities and desirable pharmacokinetics as well as activity in renal cancer and several other tumors. Ongoing trials are further evaluating pazopanib in a variety of malignancies...
  61. ncbi Recent advances in the therapy of renal cancer
    Guru Sonpavde
    US Oncology Research, Houston, Texas, USA
    Expert Opin Biol Ther 7:233-42. 2007
    ..The future of the therapy of renal cancer appears promising owing to the efficacy of these novel agents. Clinical trials designed to further assess these and other agents need to be vigorously supported...
  62. doi Diagnosis and management of urothelial carcinoma of the bladder
    Maria F Tanaka
    Department of Medicine, Section of Medical Oncology, Baylor College of Medicine, Houston, TX, USA
    Postgrad Med 123:43-55. 2011
    ..It is important for primary care physicians to recognize the early signs and symptoms of bladder carcinoma, initiate the proper work-up, and refer promptly to a urologist to evaluate suspicious signs and symptoms...
  63. doi Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics
    Matthew D Galsky
    Translational Oncology Program, US Oncology Research, Dallas, TX, USA
    Invest New Drugs 28:194-8. 2010
    ..To describe a phase II study design to evaluate the activity of novel anti-cancer agents that focuses on molecular pathogenesis rather than tumor histology...
  64. doi Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer
    Guru Sonpavde
    Department of Medicine, Division of Hematology Oncology, University of Alabama, Birmingham UAB Comprehensive Cancer Center, Birmingham, AL, USA
    BJU Int 114:E25-31. 2014
    ..To investigate the association of radiographic progression defined by Prostate Cancer Working Group (PCWG)-2 guidelines and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC)...
  65. doi Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis
    Arnoud J Templeton
    Affiliations of authors Divisions of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Department of Medicine, University of Toronto, Toronto, Canada AJT, MGM, FEV B, PA, RL A, JJK, IFT, EA Department of Medical Oncology, Institute of Oncology Ljubljana, Slovenia BS Medical Oncology University Hospital, Albacete, Spain AO University of Alabama, Birmingham Comprehensive Cancer Center, Birmingham, AL GS Department of Medical Oncology, Royal Melbourne Hospital, Melbourne, Australia BT
    J Natl Cancer Inst 106:dju124. 2014
    ..Here we quantify the prognostic impact of this biomarker and assess its consistency in solid tumors...
  66. doi Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damage
    Weiguo Jian
    Departments of aUrology bImmunology, Baylor College of Medicine, Houston, Texas cDepartment of Medicine, Division of Hematology Oncology dDepartment of Radiation Oncology, University of Alabama, Birmingham UAB Comprehensive Cancer Center, Birmingham, Alabama, USA
    Anticancer Drugs 25:878-86. 2014
    ..05). Biomarker-driven evaluation of PARP inhibitors in UC is justified as the activity of CEP-9722 correlated inversely with homologous recombination repair response to DNA damage. ..
  67. ncbi The preclinical activity of lenalidomide in indolent urothelial carcinoma
    Weiguo Jian
    Department of Urology, Baylor College of Medicine, Houston, TX, U S A
    Anticancer Res 34:3383-9. 2014
    ..Lenalidomide is an IMiD® immunomodulatory drug, which may warrant evaluation in urothelial carcinoma (UC)...
  68. ncbi The angiopoietin-TIE2 pathway is a potential therapeutic target in urothelial carcinoma
    Weiguo Jian
    Department of Urology, Baylor College of Medicine, Houston, TX, U S A
    Anticancer Res 34:3377-82. 2014
    ..We examined the pre-clinical activity of CEP-11981, a tyrosine kinase inhibitor of TIE2, FGFR1 and VEGFR-1-3, in UC...
  69. ncbi Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue
    Steven S Shen
    Department of Pathology, The Methodist Hospital and Baylor College of Medicine, Houston, Texas 77030, USA
    Cancer 106:2610-6. 2006
    ..In a previous study the selective ER modulator raloxifene was shown to induce apoptosis in an ERbeta-positive bladder cancer cell line. However, the expression of ERbeta in human bladder cancer has not been thoroughly investigated...
  70. doi Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy
    Gregory R Pond
    Department of Oncology, McMaster University and Ontario Clinical Oncology Group, Hamilton, Ontario, Canada
    BJU Int 110:E461-8. 2012
    ..Prospective validation is warranted...
  71. pmc The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way
    Sanjay N Mediwala
    Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Prostate 73:267-77. 2013
    ..The mechanism of AR-V7 constitutive activation is not known...
  72. ncbi Novel antiangiogenic agents in the treatment of refractory renal cell carcinoma
    Guru Sonpavde
    Texas Oncology, Houston, TX, USA
    Clin Genitourin Cancer 6:S29-36. 2008
    ..Additionally, novel combinations of antiangiogenic agents are emerging. The rapid expansion in the therapeutic armamentarium holds the promise of further enhancing outcomes...
  73. pmc New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib
    C Lance Cowey
    Baylor Sammons Cancer Center Texas Oncology, PA, GU Oncology Program, Dallas
    Onco Targets Ther 3:147-55. 2010
    ..In this review, the outcomes of the clinical testing of pazopanib are discussed, as well as a perspective on the placement of pazopanib among other approved agents...
  74. ncbi Germ-cell tumors
    Varuni Kondagunta
    N Engl J Med 357:1773; author reply 1773-4. 2007
  75. ncbi Problems with the randomized discontinuation design
    Guru Sonpavde
    J Clin Oncol 24:4669-70; author reply 4670-1. 2006
  76. ncbi Bevacizumab in colorectal cancer
    Guru Sonpavde
    N Engl J Med 351:1690-1; author reply 1690-1. 2004
  77. ncbi Chemotherapy for bladder cancer
    Guru Sonpavde
    N Engl J Med 349:2272-3; author reply 2272-3. 2003
  78. ncbi Prostatectomy or watchful waiting in prostate cancer
    Guru Sonpavde
    N Engl J Med 348:170-1; author reply 170-1. 2003
  79. doi Trial design for metastatic castration-resistant prostate cancer
    Guru Sonpavde
    J Clin Oncol 26:3647-8; author reply 3648-9. 2008
  80. ncbi Lapatinib plus capecitabine in breast cancer
    Guru Sonpavde
    N Engl J Med 356:1471; author reply 1471-2. 2007
  81. ncbi Bevacizumab for non-small-cell lung cancer
    Guru Sonpavde
    N Engl J Med 356:1374; author reply 1374-5. 2007
  82. ncbi Radical prostatectomy versus watchful waiting
    Guru Sonpavde
    N Engl J Med 353:1298-300; author reply 1298-300. 2005
  83. ncbi PSA and clinical responses to celecoxib in a patient with prostate cancer and bone metastases
    Guru Sonpavde
    Mayo Clin Proc 80:1100-1. 2005
  84. ncbi Treatment of advanced head and neck cancer
    Guru Sonpavde
    N Engl J Med 351:829-31; author reply 829-31. 2004
  85. ncbi Bevacizumab in renal-cell cancer
    Guru Sonpavde
    N Engl J Med 349:1674. 2003
  86. ncbi Communicating the value of adjuvant chemotherapy
    Guru Sonpavde
    Division of Hematology Oncology, Department of Internal Medicine, Maricopa County Medical Center, Phoenix, AZ, USA
    J Clin Oncol 21:948-9. 2003
  87. ncbi Breast-conserving surgery for breast cancer
    Guru Sonpavde
    N Engl J Med 348:657-60; author reply 657-60. 2003